OZTA logo

Grifols, S.A.BRSE:OZTA Stock Report

Market Cap CHF 5.5b
Share Price
n/a
1Yn/a
7D0%
1D0.5%
Portfolio Value
​
View

Grifols, S.A.

BRSE:OZTA Stock Report

Market Cap: CHF 5.5b

Grifols (OZTA) Stock Overview

Engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. More details

OZTA fundamental analysis
Snowflake Score
Valuation4/6
Future Growth4/6
Past Performance5/6
Financial Health1/6
Dividends3/6

Rewards

Trading at 73.1% below our estimate of its fair value

Earnings are forecast to grow 21.03% per year

Earnings grew by 51.8% over the past year

Risk Analysis

Interest payments are not well covered by earnings

Unstable dividend track record


OZTA Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW444,159 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.
Grow your followingReal investors. The kind who actually invest, not scroll past.
Unlock free accessFree premium subscription for consistent and quality authors.
Learn moreCreate Narrative
B
BlackGoat
R
RockeTeller
I
Investingwilly
D
davidlsander
444,159 investors already sharing narratives
View all narratives

Grifols, S.A. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Grifols
Historical stock prices
Current Share Price€9.51
52 Week High€9.51
52 Week Low€9.51
Beta1.19
1 Month Change0%
3 Month Change14.73%
1 Year Changen/a
3 Year Changen/a
5 Year Changen/a
Change since IPO14.73%

Recent News & Updates

Recent updates

Shareholder Returns

OZTACH BiotechsCH Market
7D0%-1.0%-2.5%
1Yn/a17.0%11.8%

Return vs Industry: Insufficient data to determine how OZTA performed against the Swiss Biotechs industry.

Return vs Market: Insufficient data to determine how OZTA performed against the Swiss Market.

Price Volatility

Is OZTA's price volatile compared to industry and market?
OZTA volatility
OZTA Average Weekly Movement3.6%
Biotechs Industry Average Movement6.7%
Market Average Movement3.9%
10% most volatile stocks in CH Market7.5%
10% least volatile stocks in CH Market2.0%

Stable Share Price: OZTA has not had significant price volatility in the past 3 months compared to the Swiss market.

Volatility Over Time: Insufficient data to determine OZTA's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
190925,000Nacho Abia Buenachewww.grifols.com

Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others. The company offers various hemoderivatives from human plasma for immunology, infectious diseases, hepatology, intensive care, pulmonology, hematology, and neurology treatment areas; and markets diagnostic testing equipment, reagents, and other equipment, as well as provides transfusion medicine, clinical diagnostics, and testing services.

Grifols, S.A. Fundamentals Summary

How do Grifols's earnings and revenue compare to its market cap?
OZTA fundamental statistics
Market capCHF 5.45b
Earnings (TTM)CHF 426.67m
Revenue (TTM)CHF 7.01b
14.6x
P/E Ratio
0.9x
P/S Ratio

Is OZTA overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
OZTA income statement (TTM)
Revenue€7.42b
Cost of Revenue€4.62b
Gross Profit€2.80b
Other Expenses€2.35b
Earnings€452.00m

Last Reported Earnings

Jun 30, 2026

Next Earnings Date

n/a

Earnings per share (EPS)0.66
Gross Margin37.79%
Net Profit Margin6.09%
Debt/Equity Ratio104.1%

How did OZTA perform over the long term?

See historical performance and comparison

Dividends

3.1%
Current Dividend Yield
33%
Payout Ratio

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/09/15 10:18
End of Day Share Price 2026/08/12 00:00
Earnings2026/06/30
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Grifols, S.A. is covered by 30 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Luis ArredondoBanco de Sabadell. S.A.
null nullBanco de Sabadell. S.A.
Jaime EscribanoBanco Santander